LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA® in Chinese healthy male subjects - Cao, Guoying; Wang, Jingjing; He, Jinjie; Hu, Yingying; Yang, Haijing; Que, Linling; Gu, Xianghong; Yu, Jicheng; Wu, Xiaojie; Wu, Jufang; Fang, Wei; He, Qing; et al. (Frontiers in pharmacology, 2023)
Keywords: biosimilar; immunogenicity; pharmacokinetics; Pharmacology; safety; tocilizumab; pharmacokinetics; tocilizumab; safety; immunogenicity; biosimilar